Edition:
United Kingdom

Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

0.70USD
13 Dec 2017
Change (% chg)

$0.00 (+0.71%)
Prev Close
$0.70
Open
$0.71
Day's High
$0.72
Day's Low
$0.70
Volume
29,871
Avg. Vol
86,312
52-wk High
$3.38
52-wk Low
$0.60

Select another date:

Wed, Dec 6 2017

BRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In Biocept

* SABBY MANAGEMENT LLC REPORTS A 9.20 PCT PASSIVE STAKE IN BIOCEPT INC AS OF DEC 5 - SEC FILING Source text: (http://bit.ly/2ACbgue) Further company coverage:

BRIEF-Biocept announces pricing of public offering of up to 4,925,936 shares of common stock

* BIOCEPT ANNOUNCES PRICING OF PUBLIC OFFERING OF UP TO 4,925,936 SHARES OF COMMON STOCK

BRIEF-Biocept And UC San Diego Medical Center Announce Clinical Study Collaboration To Demonstrate Utility Of Biocept's Liquid Biopsy Test In Immunotherapy

* BIOCEPT AND UC SAN DIEGO MEDICAL CENTER ANNOUNCE CLINICAL STUDY COLLABORATION TO DEMONSTRATE UTILITY OF BIOCEPT'S LIQUID BIOPSY TEST IN IMMUNOTHERAPY Source text for Eikon: Further company coverage:

BRIEF-Biocept files for offering $10 mln of shares of co's common stock and warrants

* Biocept Inc files for offering $10 million of shares of co's common stock and warrants - SEC Filing

BRIEF-Biocept reports Q3 loss per share $0.20

* Biocept Inc - ‍cash and cash equivalents were $5.9 million as of September 30, 2017​ Source text for Eikon: Further company coverage:

BRIEF-Biocept and Miraca Life Sciences enter into marketing agreement

* Biocept and Miraca Life Sciences enter into marketing agreement to expand target selector testing in the United States

BRIEF-Biocept Inc files for disposition of up to 2.9 million shares of common stock

* Biocept Inc files for disposition of up to 2.9 million shares of common stock by the selling stockholders Source text: (http://bit.ly/2fShoIH) Further company coverage:

BRIEF-Biocept, UT Southwestern Medical Center announce clinical study to profile, monitor non-small cell lung cancer patients

* Biocept and UT Southwestern medical center announce clinical study to profile and monitor non-small cell lung cancer patients with ALK rearrangements Source text for Eikon: Further company coverage:

BRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR

* Biocept enters into exclusive distribution agreement with Global Laboratory Product Supplier VWR

BRIEF-Biocept Q2 loss per share $0.21

* Says ‍revenues for Q2 of 2017 increased 93% to $1.3 million​

Select another date: